PrairieSky Royalty, a Canadian oil royalty company, reported a 33% year-over-year revenue increase to C$165 million in Q3 2026, driven mainly by high oil prices. Oil accounted for nearly 90% of revenue despite being 55% of production. The company generated C$127 million in free cash flow, enabling a significant reduction in net debt to C$90 million, with expectations to reach a net cash position by Q1 2027. The analyst rates the stock as a hold due to current valuations and limited upside at present oil prices, viewing royalty companies as safer investments during bear markets.
PrairieSky Royalty's recent financial results provide context for energy market activity. For readers following energy stocks, of 79 priced US energy-sector stocks on Pluang, 27 rose and 50 fell today. Notable movers include ENPH at USD 31.78 with a 4.47% increase and 78% buy orders, KOS at USD 2.50 down 3.47% with 93% buy orders, and UGP at USD 5.80 up 2.84% with 100% buy orders. Data is as of Nov 04, 2026 20:31 WIB.
The global AI accelerator market is projected to grow from $151 billion in 2025 to $443 billion by 2030, with a compound annual growth rate of about 24%. This expansion is fueled by the rise of generative AI, large language models, and increased inve...
No7 Software has enhanced its Anchor Loyalty & Rewards app by integrating Shopify POS, allowing merchants to run a unified loyalty program across online stores and physical shops. Customers now maintain a single points balance, tier status, and refer...
A growing town replaced its inefficient IT request process of spreadsheets and emails with a centralized Microsoft Power Apps hub developed by eSoftware Associates. This hub integrates project intake, risk assessment, and PMO scoring into one platfor...
Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
